SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
DiscoverMDT
HealthcareNYSEUSD

Medtronic plc

$0012345678900123456789.0012345678900123456789+2.8%
52w low (est.) $67.75$104.38 52w high (est.)
Peers
Market data
Market cap
$107.36B
52-week range
$73.31 – $106.33
Beta (vs market)
0.58
Sector
Healthcare
Valuation
P/E ratio
22.5x
DCF fair value
$134.09
Margin of safety
+60.5%
Forward P/E
13.1x
PEG ratio
1.62
Dividend yield
3.43%
Quality & efficiency
Moat score
69/100
Return on equity
9.8%
Profit margin
13.2%
Debt / equity
0.58
Growth & analysts
Revenue growth (YoY)
+9.9%
Analyst target
$97.73
Target upside
+17.0%
Analysts covering
26

About Medtronic plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Valuation

ValueGrowthProfitHealthIncome64QUALITY
Overall Rating
83
Strong Buy
Strong Buy
Moat Score69
DCF Intrinsic Value
$134.09+60.5% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
$107.36B
P/E Ratio
22.5
Dividend Yield
3.43%
Revenue Growth
+9.9%
Profit Margin
13.2%
ROE
9.8%
Debt / Equity
0.58
Beta
0.58
Dividend Aristocrats
vs Healthcare sector:P/E 22 vs 28 · cheaperMoat 69 vs 7Yield 3.43% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · MDT